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associations of urinary phthalate metabolites with
markers of diabetes risk: national health and
nutrition examination survey 2001–2008
Tianyi Huang1,2, Aditi R Saxena3, Elvira Isganaitis4 and Tamarra James-Todd1*Abstract
Background: Phthalates are ubiquitous endocrine disrupting chemicals associated with diabetes. Although women
and minorities are more likely to be exposed to phthalates, no prior studies have examined phthalate exposure and
markers of diabetes risk evaluating effect modification by gender and race/ethnicity.
Methods: We analyzed CDC data for 8 urinary phthalate metabolites from 3,083 non-diabetic, non-pregnant
participants aged 12- < 80 years in the National Health and Nutrition Examination Survey (NHANES) 2001–2008. We
used median regression to assess the associations between urinary phthalate metabolites and fasting blood glucose
(FBG), fasting insulin and Homeostatic Model Assessment of insulin resistance (HOMA-IR), controlling for urinary
creatinine as well as several sociodemographic and behavioral factors. Stratified analyses were conducted to
compare the gender- and race/ethnicity-specific patterns for the associations.
Results: Urinary levels of several phthalate metabolites, including MBzP, MnBP, MiBP, MCPP and ∑DEHP showed
significant positive associations with FBG, fasting insulin and HOMA-IR. No clear difference was noted between men
and women. Mexican-Americans and non-Hispanic blacks had stronger dose–response relationships for MnBP, MiBP,
MCPP and ∑DEHP compared to non-Hispanic whites. For example, the highest quartile of MiBP relative to its lowest
quartile showed a median FBG increase of 5.82 mg/dL (95% CI: 3.77, 7.87) in Mexican-Americans, 3.63 mg/dL
(95% CI: 1.23, 6.03) in blacks and 1.79 mg/dL (95% CI: -0.29, 3.87) in whites.
Conclusions: The findings suggest that certain populations may be more vulnerable to phthalates with respect
to disturbances in glucose homeostasis. Whether endocrine disrupting chemicals contribute to gender and
racial/ethnic differences in diabetes risk will be an important area for further study.
Keywords: Di(2-ethylhexyl) phthalate, Mono-benzyl phthalate, Mono-(3-carboxypropyl) phthalate, Mono-ethyl
phthalate, Mono-isobutyl phthalate, Mono-n-butyl phthalate, Insulin, Blood glucose, Gender differences, Race/ethnicityBackground
Phthalates are a family of diester compounds of 1,2-ben-
zenedicarboxylic acid widely used as plasticizers, sol-
vents or additives. They are found in cosmetics, food
wrapping, medical devices and a large number of other
consumer products [1-3]. Human exposure is detectable* Correspondence: tjames-todd@bics.bwh.harvard.edu
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stated.in urine in >75% of the U.S. population [4] and is mostly
due to the absorption, inhalation or ingestion of phtha-
lates from these products [5,6]. Moreover, phthalates
have been shown to have developmental and reproduct-
ive toxicity in experimental animals [7] and have raised
public health concerns for a variety of adverse health
outcomes, notably genitourinary malformations and in-
fertility related to anti-androgen effects [8,9], in humans.
An emerging body of evidence suggests that phthalates
may interfere with glucose homeostasis and insulinLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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[10-13]. Phthalates have been demonstrated to bind to
peroxisome proliferator-activated receptors (PPARs)
[14,15], a family of nuclear receptors that controls lipid
storage and carbohydrate metabolism [16-18]. Interac-
tions between phthalates and PPAR-gamma may contrib-
ute to dysregulation of glucose metabolism and
promotion of adipogenesis [7,17,19]. Moreover, the pre-
disposition to obesity and diabetes may be influenced by
in utero exposure to phthalates [20,21]. Although a posi-
tive association has been reported in US males between
specific phthalates and insulin resistance, as assessed by
Homeostatic Model Assessment of insulin resistance
(HOMA-IR) [22], no studies to our knowledge have ex-
amined gender and racial/ethnic differences in associa-
tions between phthalates and markers of glucose
homeostasis and insulin resistance (hereafter ‘markers of
diabetes risk’).
The importance of evaluating this research question
lies in population studies showing higher insulin resist-
ance and increased risk of type 2 diabetes in women ver-
sus men and in blacks and Hispanics compared with
whites [23-26]. While genetic and lifestyle factors have
been examined [27,28], few published studies have inves-
tigated environmental factors, such as phthalate expos-
ure, as potential contributors to the increased risk of type
2 diabetes in these populations. Interestingly, several
studies have found urinary phthalate metabolite levels to
be higher in women and non-white ethnic groups [5,29].
As such, it is essential to examine how the nearly ubiqui-
tous phthalate exposure in the U.S. population may con-
tribute to gender and racial/ethnic differences in glucose
regulation, insulin resistance and diabetes risk.
In this exploratory study, we hypothesize that in-
creased levels phthalate metabolites are associated with
higher levels of markers of diabetes risk in men and
women without the diagnosis of diabetes. Furthermore,
we posit that gender and race/ethnicity may modify the
positive associations. We examined the associations of 8
urinary phthalate metabolites with three markers of dia-
betes risk including fasting blood glucose (FBG), fasting
insulin and HOMA-IR in participants of the National
Health and Nutrition Examination Survey (NHANES)
2001–2008, and compared the patterns of these associa-
tions across gender and racial/ethnic subgroups with
evaluations of potential interactions.
Methods
Study participants
For this analysis we pooled data from 2001–2008
NHANES, a nationally representative survey conducted by
the National Center for Health Statistics (NCHS), Centers
of Disease Control and Prevention (CDC) to assess the
health and nutritional status among the civilian, non-institutionalized US population. A complex, multistage,
probability sampling strategy was used, with oversampling
of subgroups of particular public health interest, including
individuals of lower socioeconomic status and racial/
ethnic minorities.
The current analysis included men and women aged
12- < 80 years who did not carry the diagnosis of diabetes,
as the analysis suggested no differences between adoles-
cents (12–20 years) and adults in the associations of
phthalates with markers of diabetes risk. Diabetes diag-
nosis was based on participants’ answer to the question:
“Other than during pregnancy, have you ever been told
by a doctor or health professional that you have diabetes
or sugar diabetes?” We included only those participants
who responded ‘no’ to self-reported diabetes. For women
of reproductive age (defined by NHANES as 20–44 years
for 2007–2008 cycle and 12–59 years for all other cycles),
only those with confirmed negative urine pregnancy tests
were included in this analysis.
Measurements of phthalate exposure
Urinary phthalate metabolites were measured in a ran-
dom, one-third subsample of NHANES participants.
Urine samples were collected and stored at −20°C before
being shipped to CDC's National Center for Environmen-
tal Health for analysis. Laboratory testing results below
limits of detection (LOD) were replaced with LOD divided
by the square root of 2 [30]. Details regarding phthalate
measurements can be found elsewhere [5].
We selected the following 8 phthalate metabolites that
were measured in all NHANES cycles from 2001 to 2008:
mono-ethyl phthalate (MEP), mono-n-butyl phthalate
(MnBP), mono-isobutyl phthalate (MiBP), mono-benzyl
phthalate (MBzP), mono-(3-carboxypropyl) phthalate
(MCPP), mono-(2-ethyl-hexyl) phthalate (MEHP), mono-
(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono-
(2-ethyl-5-oxohexyl) phthalate (MEOHP). The latter three
metabolites of di-2-ethylhexyl phthalates (DEHP), MEHP,
MEHHP and MEOHP, were combined into one measure
in molar concentrations for analysis, denoted by ∑DEHP.
Phthalate metabolites were divided into quartiles with the
lowest category as the reference level. To account for the
influence of urine volume and renal function on phthalate
measurement, we reported creatinine-adjusted levels by
dividing the phthalate concentration by urinary creatinine
concentration.
Markers of diabetes risk
Fasting blood samples were collected during the morning
examination session with measurement of FBG (mg/dL)
and insulin levels (uU/mL). Among the study participants,
6.4% were fasted <8 hours at the time of blood sample
collection, and 3.2% had either FBG > 126 mg/dL or
hemoglobin A1c > 6.5%. Since exclusions of these
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kept them in the analysis with appropriate statistical ma-
nipulations (described below) to minimize their possible
influences. To quantify insulin resistance, we calculated
Homeostatic Model Assessment of insulin resistance
(HOMA-IR) with the following equation [31]:
HOMA ¼ Fasting glu cose mml=Lð Þ  Fasting insulin uU=mlð Þ
22:5
FBG, insulin and HOMA-IR were all evaluated as con-
tinuous outcomes.
Covariates
Covariates used in the analysis include age, gender, race/
ethnicity, fasting time, urinary creatinine, total caloric in-
take, triglyceride, smoking status, education and poverty.
Total fat intake and physical activity were also considered
but not used in analysis, as they did not change the effect
estimates substantially or contribute to the models as
strong predictors. Age was categorized as 12- < 20, 20- <
60 and 60- < 80 years. Self-identified race/ethnicity was
categorized as non-Hispanic white, non-Hispanic black,
Mexican-Americans and other. To account for the varia-
tions in fasting time, as well as the small proportion of
participants who fasted < 8 hour, we created a single con-
tinuous measure for fasting time.
Total caloric intake, estimated by 24-hour dietary re-
call in 2001–2002 and by the average caloric intake from
the 2-day recall in 2003–2008, was categorized into
quartiles. We created quartiles for triglyceride levels.
Smoking status was defined as never smoker, current
smoker and past smoker, with the addition of an “N/A”
category for participants under 20 for whom data on
smoking history were not available. We evaluated educa-
tion as high school graduate or less, some college, col-
lege graduate or higher and unfinished education for
participants under 20. Poverty was determined based on
income-to-poverty ratio, with the ratio ≤ 1 being under
the poverty level [32].
Body mass index (BMI) may be an important intermedi-
ate or confounding variable for the associations under
investigation. We divided BMI into four categories: under-
weight, normal weight, overweight, and obese, using BMI
cutoff points (<18.5, 18.5-25, 25–30 and ≥30 kg/m2) for
adults and percentile cutoff points (<5th, 5th-85th, 85th-
95th, and ≥95th percentile) for adolescents [33].
Statistical analysis
We conducted a complete-subject analysis based on eli-
gible subjects without missing covariate information.
Population characteristics across gender and racial/ethnic
categories (non-Hispanic white, non-Hispanic black,
Mexican-American and other) were presented in me-
dians and interquartile ranges.We used median regression to reduce the impact of the
non-normal, highly-skewed diabetes biomarker levels,
allowing the robust modeling of continuous outcomes on
their measured scale [34-36]. The analyses were con-
ducted separately for each phthalate. Median regression
was performed for each of the markers of diabetes risk
across phthalate quartiles based on raw concentrations,
adjusted for age, gender, race/ethnicity, fasting time, urin-
ary creatinine [37], total caloric intake, triglycerides,
education, poverty and smoking status in all phthalate
models. The coefficient for a given phthalate quartile
represents the median change of the markers of diabetes
risk comparing that phthalate quartile to the lowest quar-
tile after accounting for the other factors in the model.
Markov Chain Marginal Bootstrap (MCMB) re-sampling
method was used to compute 95% confidence intervals
(95% CI), and p-values for trend across phthalate quartiles
were reported by using the median value in each category
as a single continuous variable. Multiple comparisons
were not adjusted for in the analysis, given the exploratory
nature of the study [38]. We also ran models that further
included BMI, which could not be ruled out as potential
confounders or intermediates given the cross-sectional
design.
To evaluate the gender and racial/ethnic differences in
the associations between phthalates and markers of dia-
betes risk, we conducted stratified analyses using the same
model in the two gender groups (males and females) and
the three major racial/ethnic groups (white, black and
Mexican-American). ‘Other’ race/ethnicity group was not
considered due to its small sample size and mixed com-
position. We used the quartiles derived from the phthalate
distribution of the overall population in the stratified ana-
lysis. We also repeated the analysis by creating gender-
and race/ethnicity-specific quartiles for each phthalate.
Associations were slightly stronger, but for consistency, we
reported the results based on overall-population quartiles.
In addition, we added cross-product terms to evaluate the
effect modification by gender and race/ethnicity, respect-
ively, interpreting p < 0.10 from likelihood ratio test as a
significant interaction. All analyses were conducted in
SAS 9.2 (Cary, NC).
Results
Population characteristics
Of 3,870 participants between ages 12 and <80 having
data on urinary phthalate metabolites, fasting glucose
and insulin levels, we excluded n = 322 people who self-
reported ‘yes’ or ‘borderline’ for diabetes diagnosis status,
refused, or had missing information. We additionally ex-
cluded n = 146 women of reproductive age who had posi-
tive, invalid or missing pregnancy tests or who were
eligible but had not completed the tests. Another n = 3
current insulin users were also excluded, which left n =
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of missing covariates, resulting in a total of n = 3,083
study participants for this analysis.
Women had higher creatinine-adjusted concentrations
for all six selected phthalate metabolites than men (Table 1).
Men had higher FBG levels, but lower fasting insulin levels,
which contributed to slightly smaller measures of HOMA-
IR compared to women. Levels of phthalate metabolites also
varied across the three major ethnic groups, with blacks
having the highest levels of MEP, MnBP, MiBP, MBzP, and
∑DEHP and whites having the highest MCPP levels.
Mexican-Americans had higher urinary concentrationsTable 1 Study population characteristics across gender and r
Gender
Men
(n = 1620)
Women
(n = 1463)
Wh
(n =
Phthalate metabolites*
MEP 125.3 181.9 12
(57.8, 340.9) (89.0, 425.6) (55.0,
MBzP 10.4 13.4 1
(5.4, 19.5) (7.1, 23.8) (6.0,
MnBP 13.6 22.3 1
(8.7, 22.3) (13.2, 35.9) (9.6,
MiBP 3.8 4.9 3
(2.0, 6.6) (2.6, 8.9) (1.8
MCPP 2.0 2.3 2
(1.2, 3.3) (1.4, 4.0) (1.4
∑DEHP 9.5 11.5 1
(5.3, 19.7) (6.5, 23.1) (5.7,
Markers of diabetes risk
Fasting glucose (mg/dL) 96.9 93.0 9
(91.0, 104.0) (88.0, 100.0) (90.1,
Fasting insulin (uU/mL) 9.3 9.9 8
(6.0, 14.4) (6.4, 15.2) (5.6,
HOMA-IR 2.2 2.3 2
(1.4, 3.6) (1.4, 3.7) (1.3
Selected covariates
Age (yrs) 33 34 4
(18, 52) (18, 51) (23
BMI (kg/m2)** 26.0 26.5 2
(22.2, 29.8) (22.1, 31.6) (22.6
Total caloric intake (kcal) 2399 1720 21
(1845, 3099) (1342, 2187) (1591
Creatinine (mg/dL) 147 116 1
(103, 208) (72, 173) (75,
*Creatinine-adjusted phthalates: μg/g creatinine for MEP, MBzP, MnBP, MiBP and M
**Number of subjects for BMI is slightly different due to missing values: male (1607)of MnBP and MiBP than whites. With regard to the
markers of diabetes risk, Mexican-Americans and blacks
had comparable levels of fasting insulin, but Mexican-
Americans had higher levels of FBG. Whites had similar
levels of FBG to African-Americans, but lower fasting insu-
lin levels. Mexican-Americans yielded the highest measures
of HOMA-IR, while whites were lowest in HOMA-IR.
Phthalate metabolites and markers of diabetes risk in the
overall population
Associations of each diabetes biomarker across quartiles
of phthalates for those without self-reported diabetes areacial/ethnic groups, NHANES 2001-2008
Race/ethnicity
ite
1362)
Black
(n = 719)
Mexican-American
(n = 726)
Other
(n = 276)
Median (interquartile range)
2.3 190.4 186.7 141.8
325.7) (88.2, 428.1) (86.6, 446.4) (64.0, 346.6)
1.5 13.1 11.0 12.0
20.9) (7.2, 23.6) (5.5, 20.4) (6.1, 23.3)
6.0 18.4 17.4 19.6
26.3) (11.2, 28.6) (10.5, 29.9) (12.0, 32.6)
.5 5.0 4.6 6.4
, 6.1) (2.8, 8.8) (2.4, 8.0) (3.3, 11.0)
.3 1.9 2.2 2.1
, 3.9) (1.1, 3.2) (1.3, 3.7) (1.3, 3.9)
0.2 11.4 9.8 11.4
22.6) (5.8, 23.2) (5.8, 17.8) (7.1, 22.3)
6.0 92.0 95.7 95.0
103.2) (87.0, 99.0) (90.7, 102.0) (90.0, 102.0)
.6 10.4 10.8 8.9
13.2) (6.5, 17.1) (7.1, 16.3) (5.9, 13.9)
.1 2.3 2.6 2.1
, 3.3) (1.4, 4.0) (1.7, 4.0) (1.4, 3.3)
2 24 25 32
, 59) (16, 46) (16, 44) (18, 49)
6.1 26.0 26.4 25.6
, 30.3) (21.8, 31.8) (22.1, 30.3) (21.7, 29.2)
01 1972 2028 1903
, 2764) (1459, 2680) (1546, 2614) (1401, 2617)
25 165.0 124.0 132
176) (110, 234) (84, 175) (89, 185)
CPP; μmol/100 g creatinine for ∑DEHP.
, female (1447); white (1352), black (710), Mexican-American (710), other (271).
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for MnBP, MiBP, MCPP and ∑DEHP with FBG, fasting
insulin and HOMA-IR. MiBP was most stronglyTable 2 Associations of phthalates with markers of
diabetes risk in the overall population, NHANES 2001-2008
Phthalate
metabolites*
Biomarkers for diabetes
Fasting glucose Fasting insulin HOMA-IR
Median change (95% CI)**
MEP
Q1 Ref. Ref. Ref.
Q2 1.30 (0.15, 2.46) 0.25 (−0.50, 0.99) 0.11 (−0.06, 0.27)
Q3 0.38 (−0.75, 1.51) 0.34 (−0.35, 1.02) 0.10 (−0.07, 0.28)
Q4 0.49 (−0.80, 1.77) 0.60 (−0.13, 1.34) 0.20 (0.03, 0.38)
p for trend 0.7589 0.1480 0.0477
MBzP
Q1 Ref. Ref. Ref.
Q2 −0.30 (−1.48, 0.87) 0.77 (0.16, 1.39) 0.21 (0.06, 0.37)
Q3 −0.06 (−1.25, 1.13) 1.09 (0.39, 1.79) 0.26 (0.09, 0.44)
Q4 −0.24 (−1.49, 1.02) 1.44 (0.50, 2.38) 0.37 (0.15, 0.59)
p for trend 0.7058 0.0070 0.0028
MnBP
Q1 Ref. Ref. Ref.
Q2 0.95 (−0.22, 2.13) 1.15 (0.52, 1.78) 0.28 (0.11, 0.44)
Q3 1.70 (0.51, 2.89) 1.41 (0.72, 2.09) 0.28 (0.11, 0.46)
Q4 1.91 (0.51, 3.31) 1.11 (0.31, 1.92) 0.34 (0.15, 0.54)
p for trend 0.0193 0.0918 0.0059
MiBP
Q1 Ref. Ref. Ref.
Q2 1.87 (0.83, 2.92) 1.45 (0.85, 2.04) 0.38 (0.23, 0.52)
Q3 2.77 (1.75, 3.80) 1.23 (0.57, 1.89) 0.35 (0.19, 0.51)
Q4 3.69 (2.60, 4.78) 1.73 (0.92, 2.54) 0.53 (0.33, 0.72)
p for trend <0.0001 0.0028 0.0002
MCPP
Q1 Ref. Ref. Ref.
Q2 0.72 (−0.44, 1.89) 0.90 (0.24, 1.55) 0.23 (0.06, 0.40)
Q3 0.94 (−0.34, 2.21) 1.31 (0.59, 2.03) 0.34 (0.16, 0.52)
Q4 2.42 (1.22, 3.62) 0.94 (0.12, 1.77) 0.28 (0.07, 0.48)
p for trend <0.0001 0.0629 0.0269
∑DEHP
Q1 Ref. Ref. Ref.
Q2 1.47 (0.30, 2.63) 1.74 (1.04, 2.45) 0.49 (0.31, 0.66)
Q3 1.75 (0.66, 2.84) 1.99 (1.31, 2.66) 0.51 (0.34, 0.69)
Q4 2.45 (1.29, 3.60) 2.60 (1.82, 3.38) 0.68 (0.47, 0.88)
p for trend 0.0016 <0.0001 <0.0001
*All analyses adjusted for age, sex, race, urinary creatinine, fasting time, total
caloric intake, triglyceride, education, smoking status and poverty.
**Fasting glucose: mg/dL, fasting insulin: uU/mL.associated with FBG, with a median increase of 1.87
(95% CI 0.83-2.92), 2.77 (95% CI 1.75-3.80) and 3.69
(95% CI 2.60-4.78) mg/dL in quartiles 2–4, respectively,
compared to quartile 1 (p-trend < 0.0001). Compared to
the lowest quartile, higher quartiles of ∑DEHP were as-
sociated with higher fasting insulin levels (p-trend <
0.0001). ∑DEHP also had the most significant associa-
tions with HOMA-IR; the median values were 0.49 (95%
CI 0.31, 0.66), 0.51 (95% 0.34, 0.69) and 0.68 (95% CI
0.47, 0.88) units higher with increasing quartiles of me-
tabolite concentrations compared to the lowest quartile
(p-trend < 0.0001). While most phthalates showed a
strong positive association with all three markers of dia-
betes risk, MBzP was not associated with FBG and MEP
did not show statistically significant associations with
any of the markers of diabetes risk. Adjustment for BMI
modestly attenuated almost all associations (results not
shown).
Phthalate metabolites and markers of diabetes risk by
gender
Most of the positive associations that had previously
been observed in the overall population were also seen
in gender subgroups. For the majority of these associa-
tions, the strengths were similar in men and women, al-
though the exact dose–response patterns varied by
gender. For example, the fourth quartile of ∑DEHP was
associated with a HOMA-IR increase of 0.67 (95% CI
0.43, 0.91) in men and 0.68 (95% CI 0.38, 0.98) in women
(Figure 1-a), but there seemed to be a maximal dose–re-
sponse plateau in men, while the increasing trend was ap-
preciably linear in women (p for interaction = 0.06).
Notably, the strengths of three associations were suggest-
ively different by gender group. For example, stronger as-
sociations were seen in women for MBzP with fasting
insulin (p for interaction = 0.02), with the fourth quartile
conferring a 1.69 (95% CI 0.41, 2.98) uU/mL increase in
women compared to a 0.99 (95% CI −0.21, 2.19) uU/mL
increase in men (Figure 1-b). On the other hand, men ap-
peared to have stronger associations for ∑DEHP and FBG
than women (p for interaction = 0.04, Figure 1-c). How-
ever, these potential gender differences were not consist-
ently observed across phthalate metabolites or across
markers of diabetes risk. The complete results were given
in Additional file 1.
Phthalate metabolites and markers of diabetes risk by
race/ethnicity
For MnBP, MiBP, MCPP and ∑DEHP, the positive associ-
ations with FBG appeared to be strongest in Mexican-
Americans, intermediate in blacks, and weakest in
whites. For example, compared to the lowest quartile,
the highest quartile of MiBP was associated with a me-
dian FBG increase of 5.82 (95% CI 3.77, 7.87, p-trend <
∑DEHP and HOMA-IR
b 
c
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Figure 1 Change in markers of diabetes risk across quartiles of
markers of diabetes risk in men and women. One example is
selected for each pattern. (a) example of similar strength of
association: ∑DEHP and HOMA-IR, most associations show similar
gender patterns, (b) example of stronger association in women:
MBzP and fasting insulin, (c) example of stronger association in men:
∑DEHP and FBG. Adjusted for age, race, urinary creatinine, fasting
time, total caloric intake, triglyceride, education, smoking status and
poverty for all phthalate metabolites.
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of 3.63 (95% CI 1.23, 6.03, p-trend = 0.02) mg/dL in
blacks and a non-significant increase of 1.79 (95% CI
−0.29, 3.89, p-trend = 0.37) mg/dL in whites (Figure 2-a).
Similar racial patterns were consistently seen for MnBP,
MCPP and ∑DEHP. No significant associations were
present for MEP or MBzP in any racial/ethnic category.Depending on the type of phthalate metabolites, either
Mexican-Americans or blacks showed stronger dose–re-
sponse associations with fasting insulin compared to
whites. Significant monotonic positive trends were ob-
served for ∑DEHP in all three racial/ethnic groups, and
the associations between ∑DEHP and fasting insulin ap-
peared to be larger in magnitude among blacks and
Mexican-Americans than among whites (Figure 2-b).
There was a suggestion of a strong non-monotonic asso-
ciation for MnBP and fasting insulin only in Mexican
Americans, with those in the third quartile being 3.04
uU/mL higher (95% CI 1.51, 4.57). On the other hand,
MiBP had a monotonically increasing pattern only in
Mexican-Americans (p-trend = 0.15) and MCPP had a
similar pattern only in blacks (p-trend = 0.01), whereas
these two phthalates had non-monotonic and non-
significant positive associations with fasting insulin
among whites. Positive, but weaker associations were
seen for MBzP and insulin levels across all racial/ethnic
groups. There did not appear to be any significant asso-
ciations for MEP and insulin levels.
The race-specific associations between HOMA-IR and
phthalate metabolites revealed almost the same patterns
as reported for fasting insulin. Of all six phthalate me-
tabolites, ∑DEHP was associated with the strongest ele-
vations of HOMA-IR across three racial groups, with
the fourth quartile conferring a median increase of 0.81
(95% CI 0.38, 1.24) in blacks, 0.91 (95% CI 0.37, 1.45) in
Mexican-Americans and 0.53 (95% CI 0.26, 0.81) in
whites compared to the lowest quartile (Figure 2-c). The
associations with HOMA-IR were also strongest in
blacks or Mexican-Americans for the other five phthal-
ate metabolites except MBzP, the fourth quartile of
which was associated with the greatest increase of 0.39
(95% CI 0.09, 0.69) in whites. However, despite the sug-
gestively stronger dose–response associations in blacks
and Mexican-Americans, we did not find statistically sig-
nificant interactions by race/ethnicity for any phthalate
metabolite in relation to the three biomarkers, except
for the interaction with MnBP for HOMA-IR (p for
interaction = 0.09). The complete results were given in
Additional file 2.
Discussion
This exploratory analysis of NHANES 2001–2008 sug-
gests that higher levels of certain phthalate metabolites
were associated with elevated FBG, fasting insulin and
insulin resistance, with some variations by race/ethnicity
and less by gender. Specifically, among the phthalate
metabolites examined, MnBP, MiBP, MCPP and ∑DEHP
exhibited strong positive associations with FBG, fasting
insulin and HOMA-IR. MBzP was associated with fast-
ing insulin and HOMA-IR only. The strength of associa-
tions between levels of phthalate metabolites and
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Figure 2 Change in markers of diabetes risk across quartiles of urinary phthalate metabolites in racial/ethnic subgroups. One example
is selected for each diabetes biomarker, and similar racial/ethnic patterns were seen for other urinary phthalate metabolites, particularly MnBP,
MiBP, MCPP and ∑DEHP. (a) example of FBG: MiBP and FBG, (b) example of fasting insulin: ∑DEHP and fasting insulin, (c) example of HOMA-IR:
∑DEHP and HOMA-IR. Adjusted for age, sex, urinary creatinine, fasting time, total caloric intake, triglyceride, education, smoking status and poverty
for all phthalate metabolites.
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http://www.ehjournal.net/content/13/1/6markers of diabetes risk appeared to be mostly the same
by gender. By contrast, we noted differences in associa-
tions by racial/ethnic group, with non-Hispanic blacks
and Mexican-Americans having stronger associations
than non-Hispanic whites. These results may suggest
that phthalates could be involved in altering glucose
homeostasis and insulin sensitivity, with certain popula-
tions being more vulnerable.
Our study found similar associations as a recent study
of adult women in the NHANES 2001–2008 [10], which
showed that MiBP and ∑DEHP were associated with in-
creased insulin resistance. However, MnBP and MCPPwere not found to be positively associated with either
fasting glucose or HOMA-IR in that study, possibly due
to the restrictions by sample size. Also, the present study
showed stronger dose–response associations. A study of
only male participants from NHANES 1999–2002 found
that MBzP, MnBP and MEP were associated with in-
creased HOMA-IR [22], whereas our results revealed
non-significant positive associations for MEP.
The present study adds to the growing body of literature
showing phthalates being positively associated with dia-
betes and its risk factors [10-12,22]. One way that phtha-
lates could operate to alter normal glucose metabolism
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to bind to PPAR-alpha and PPAR-gamma [14,15]. While
PPAR-gamma agonists have great therapeutic potential in
the treatment of type 2 diabetes for their potent insulin-
sensitizing activity and anti-diabetic effects [18], it is
unclear whether phthalates modulate PPAR-gamma in the
same way. As such, more studies are needed to determine
the consequences of phthalates binding to PPAR in
humans, particularly with respect to selective PPAR-
gamma modulation [39]. Furthermore, more research
needs to be conducted on PPAR-alpha and its response
to phthalates.
Although we observed similar strengths in the associa-
tions between a majority of phthalate metabolites and
markers of diabetes risk, a few exceptions seem to show
stronger associations in women (e.g. MiBP/fasting insu-
lin and MBzP/fasting insulin) or in men (e.g., ∑DEHP/
FBG and MCPP/HOMA-IR). Although these few gender
differences may be chance findings due to inflated type I
errors from large number of statistical tests, one possible
explanation could be that the fat distribution induced by
phthalate exposure and subsequent insulin resistance
may vary by gender [40]. Indeed, visceral versus subcuta-
neous fat mass is known to differ between men and
women [41]. Another possibility lies in potential interac-
tions of anti-androgenic effect by phthalates with modu-
lation of insulin resistance [42] or glucose uptake [43].
Further investigation is needed to better understand
these gender differences in phthalate-markers of diabetes
risk associations.
Our analysis suggests racial/ethnic differences in
markers of diabetes risk according to exposure levels of
specific phthalates. Such racial/ethnic differences are un-
likely to be explained solely by the higher phthalate
levels in minorities, as the use of racial/ethnic-specific
quartiles yielded similar associations to the use of
population-specific quartiles. Also, the observed differ-
ences cannot be simply explained by the fat distribution
hypothesis as postulated for gender differences, because
a number of studies suggest non-Hispanic whites have
higher visceral fat and liver fat than blacks and Mexican-
Americans [41,44,45]. It is possible that the prevalence
of certain susceptibility gene variants, such as Pro12Ala
in PPAR-gamma gene that has been associated with type
2 diabetes risk and its intermediate traits [46,47], may
vary by race/ethnicity [48]. However, these racial/ethnic
differences need to be further explored.
The present exploratory study has several limitations.
First, given the cross-sectional design of the study, we can-
not make any causal interpretations for the observed asso-
ciations. Second, the quickly metabolizing and excreting
nature of phthalates [4,9], as well as the one-time collec-
tion of urine samples, does not provide reliable inference
for the long-term exposure to phthalates [49]. Also,difference in urinary levels of phthalates metabolites may
reflect differences in phthalate metabolism and excretion
in addition to differences in phthalate exposure. Third, the
existence of undiagnosed cases of diabetes [50] in our pre-
sumably metabolically normal participants might result in
misclassification and overestimate the true associations,
given that people with undiagnosed diabetes may have in-
creased phthalate exposures through the use of medical
devices and medications for co-morbid conditions [51], as
well as greatly elevated levels of markers of diabetes risk.
However, sensitivity analyses excluding participants with
FBG > 126 mg/dL or hemoglobin A1c > 6.5% show negli-
gible changes in the results. Phthalate exposures through
medical devices and medications for other chronic dis-
eases may also confound the association. Finally, we must
interpret the results with caution, because statistically sig-
nificant interactions were not noted despite consistent
findings for racial/ethnic differences, likely due to in-
creased degrees of freedom when phthalate exposures
were assessed in quartiles and limited sample size in mi-
nority groups. Also, the possibility of chance findings can-
not be ruled out as we did not adjust for multiple
comparisons in the analysis.
The strength of this study includes an analysis of a
large, representative U.S. population, in which we evalu-
ated the association between 8 phthalate metabolites and
3 markers of diabetes risk. The pooling of 8-years of
NHANES data provides better power for more elaborate
assessment within gender and racial/ethnic strata. To our
knowledge, this is one of the first studies to evaluate the
association between phthalate metabolites and markers
of diabetes risk evaluating effect modification by gender
and race/ethnicity. Other strengths include our ability to
account for a wide range of related covariates, including
important risk factors and potential confounders avail-
able in NHANES 2001–2008. Furthermore, the median
regression model, combined with exposure assessment in
categories, was utilized to obtain easy-to-interpret and
robust estimates that were less sensitive to potential out-
liers due to undiagnosed diabetes.
Conclusions
In conclusion, the present exploratory study provides
evidence for the potential impact of phthalates on glu-
cose homeostasis and insulin resistance. The metabolic
responses to this hypothesized phthalate effect, mea-
sured by FBG, fasting insulin and HOMA-IR, may vary
by race/ethnicity and in some instances by gender. Fu-
ture investigation should confirm our findings and look
into the underlying mechanisms in both experimental
and observational studies. If replicated in prospective
studies and supported by mechanistic research, our re-
sults may suggest that reductions in concentrations of
certain phthalate metabolites could improve glucose
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http://www.ehjournal.net/content/13/1/6homeostasis and reduce type 2 diabetes risk, with a po-
tentially stronger impact on more vulnerable subgroups
of the population.
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markers of diabetes risk by gender, NHANES 2001–2008.
Additional file 2: Association of urinary phthalate metabolites with
markers of diabetes risk by race/ethnicity, NHANES 2001–2008.
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